Related Experiment Video
Updated: May 1, 2026
Large Scale Zebrafish-Based In vivo Small Molecule Screen
Published on: December 30, 2010
A zebrafish chemical suppressor screening identifies small molecule inhibitors of the Wnt/β-catenin pathway
Naoyuki Nishiya1, Yusuke Oku1, Yusuke Kumagai1
1Department of Microbial Chemical Biology and Drug Discovery, Iwate Medical University School of Pharmacy, Yahaba, Iwate 028-3694, Japan.
Abstract:
Genetic screening for suppressor mutants has been successfully used to identify important signaling regulators. Using an analogy to genetic suppressor screening, we developed a chemical suppressor screening method to identify inhibitors of the Wnt/β-catenin signaling pathway. We used zebrafish embryos in which chemically induced β-catenin accumulation led to an "eyeless" phenotype and conducted a pilot screening for compounds that restored eye development. This approach allowed us to identify geranylgeranyltransferase inhibitor 286 (GGTI-286), a geranylgeranyltransferase (GGTase) inhibitor. Our follow-up studies showed that GGTI-286 reduces nuclear localization of β-catenin and transcription dependent on β-catenin/T cell factor in mammalian cells. In addition to pharmacological inhibition, GGTase gene knockdown also attenuates the nuclear function of β-catenin. Overall, we validate our chemical suppressor screening as a method for identifying Wnt/β-catenin pathway inhibitors and implicate GGTase as a potential therapeutic target for Wnt-activated cancers.
Insights
Researchers developed a chemical suppressor screening method to find Wnt/β-catenin pathway inhibitors. They identified geranylgeranyltransferase inhibitor 286 (GGTI-286), a potential therapeutic target for Wnt-activated cancers.
Area of Science:
- Molecular Biology
- Genetics
- Pharmacology
Background:
- Genetic suppressor screening identifies signaling regulators.
- The Wnt/β-catenin pathway is crucial in development and disease.
- Inhibitors of this pathway are sought for therapeutic applications.
Purpose of the Study:
- To develop a chemical suppressor screening method for Wnt/β-catenin pathway inhibitors.
- To identify novel compounds targeting this pathway using a zebrafish model.
- To validate geranylgeranyltransferase (GGTase) as a therapeutic target.
Main Methods:
- Developed a chemical suppressor screening approach analogous to genetic screening.
- Utilized zebrafish embryos with chemically induced β-catenin accumulation and an 'eyeless' phenotype.
- Screened for compounds that restored eye development, identifying GGTI-286.
Main Results:
- Identified geranylgeranyltransferase inhibitor 286 (GGTI-286) as a Wnt/β-catenin pathway inhibitor.
- GGTI-286 reduced nuclear β-catenin localization and TCF-dependent transcription in mammalian cells.
- GGTase gene knockdown also inhibited nuclear β-catenin function.
Conclusions:
- Validated chemical suppressor screening as an effective method for Wnt/β-catenin pathway inhibitor discovery.
- Demonstrated that GGTase is a potential therapeutic target for Wnt-activated cancers.
- Highlighted the role of GGTase in regulating β-catenin nuclear function.
